NCT07192471 2026-04-20
A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
Kyowa Kirin Co., Ltd.
Phase 1 Not yet recruiting
Clinical Trials
13 trialsNCT07518329 2026-04-08
Study of ALA-101 in Patients With CD19 Positive Non-Hodgkin Lymphoma and Leukemia.
Arovella Therapeutics Ltd
Phase 1 Not yet recruiting
NCT07509151 2026-04-03
SOUNDTRACK-C1
AstraZeneca
Phase 3 Not yet recruiting
NCT07333469 2026-01-13
A Clinical Study of HX111 in Patients With Advanced Solid Tumor and Lymphoma
Hanx Biopharmaceuticals (Wuhan) Co., Ltd.
Phase 1/2 Not yet recruiting
NCT07244380 2025-11-24
Phase II Trial of S101 Autologous Anti-CD7 CAR-T Cells in Patients With R/R T-LBL/ALL.
Hebei Senlang Biotechnology Inc., Ltd.
Phase 2 Not yet recruiting
NCT07196111 2025-09-29
BAFFR CAR-T Treatment for Relapsed/Refractory B-cell Tumors
Guangzhou Bio-gene Technology Co., Ltd
Phase EARLY_PHASE1 Not yet recruiting
NCT07107204 2025-09-17
A Clinical Study of BT02 in Patients With Relapsed or Refractory Hematologic Malignancies
Biotroy Therapeutics
Phase 1/2 Not yet recruiting
NCT07048353 2025-07-02
CAR-T，MTD
Shandong Qilu Cell Therapy Engineering Technology Co., Ltd
Phase EARLY_PHASE1 Not yet recruiting
NCT05545202 2024-04-03
A Randomized, Comparative, Double-blind Trial of Pentaisomaltose and Dimethyl Sulphoxide for Cryoprotection of Hematopoietic Stem Cells in Subjects With Multiple Myeloma or Malignant Lymphoma With a Need for Autologous Transplantation
Pharmacosmos A/S
Phase 4 Not yet recruiting
NCT05979857 2023-11-22
Study of SP-3164 in Relapsed or Refractory Non-Hodgkin's Lymphoma
Salarius Pharmaceuticals, LLC
Phase EARLY_PHASE1 Not yet recruiting
NCT06070246 2023-10-06
Navigating the Clinical Research Process for Lymphoma
Power Life Sciences Inc.
Not yet recruiting
NCT05788107 2023-08-09
Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of HLX51 in Patients With Solid Tumor or Lymphoma
Shanghai Henlius Biotech
Phase 1 Not yet recruiting
NCT05055791 2021-09-24
A Study to Evaluate the Safety and Tolerance of SYHX1903 in Patients With Relapsed/Refractory Hematologic Malignancies
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 1/2 Not yet recruiting